# Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

> **NCT02003222** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 488 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

## Interventions

- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **PROCEDURE:** Biospecimen Collection
- **BIOLOGICAL:** Blinatumomab
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Daunorubicin
- **DRUG:** Daunorubicin Hydrochloride
- **DRUG:** Dexamethasone
- **DRUG:** Etoposide
- **DRUG:** Leucovorin Calcium
- **PROCEDURE:** Lumbar Puncture
- **DRUG:** Mercaptopurine
- **DRUG:** Methotrexate
- **DRUG:** Pegaspargase
- **DRUG:** Prednisone
- **BIOLOGICAL:** Rituximab
- **DRUG:** Vincristine
- **DRUG:** Vincristine Sulfate

## Key facts

- **NCT ID:** NCT02003222
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-05-19
- **Primary completion:** 2023-06-23
- **Final completion:** 2027-02-25
- **Target enrollment:** 488 (ACTUAL)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02003222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02003222, "Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02003222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*